- Home
- DMF vs ACIU Comparison
DMF vs ACIU Comparison
Compare DMF & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMF
- ACIU
- Stock Information
- Founded
- DMF 1988
- ACIU 2003
- Country
- DMF United States
- ACIU Switzerland
- Employees
- DMF N/A
- ACIU N/A
- Industry
- DMF Finance/Investors Services
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- DMF Finance
- ACIU Health Care
- Exchange
- DMF Nasdaq
- ACIU Nasdaq
- Market Cap
- DMF 143.6M
- ACIU 168.7M
- IPO Year
- DMF N/A
- ACIU 2016
- Fundamental
- Price
- DMF $6.93
- ACIU $1.88
- Analyst Decision
- DMF
- ACIU Strong Buy
- Analyst Count
- DMF 0
- ACIU 1
- Target Price
- DMF N/A
- ACIU $12.00
- AVG Volume (30 Days)
- DMF 60.7K
- ACIU 115.4K
- Earning Date
- DMF 01-01-0001
- ACIU 08-05-2025
- Dividend Yield
- DMF 2.66%
- ACIU N/A
- EPS Growth
- DMF N/A
- ACIU N/A
- EPS
- DMF 0.15
- ACIU N/A
- Revenue
- DMF N/A
- ACIU $32,014,254.00
- Revenue This Year
- DMF N/A
- ACIU N/A
- Revenue Next Year
- DMF N/A
- ACIU $533.21
- P/E Ratio
- DMF $45.13
- ACIU N/A
- Revenue Growth
- DMF N/A
- ACIU 91.20
- 52 Week Low
- DMF $5.37
- ACIU $1.43
- 52 Week High
- DMF $6.79
- ACIU $4.41
- Technical
- Relative Strength Index (RSI)
- DMF 45.82
- ACIU 51.75
- Support Level
- DMF $6.86
- ACIU $1.83
- Resistance Level
- DMF $6.97
- ACIU $2.10
- Average True Range (ATR)
- DMF 0.05
- ACIU 0.15
- MACD
- DMF 0.00
- ACIU -0.00
- Stochastic Oscillator
- DMF 61.04
- ACIU 44.44
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.